medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

ACE2 expression by colonic epithelial cells is associated with
viral infection, immunity and energy metabolism
Jun Wang1#, Shanmeizi Zhao1#, Ming Liu1, Zhiyao Zhao1, Yiping Xu2, Ping Wang3, Meng Lin1,
Yanhui Xu1, Bing Huang1, Xiaoyu Zuo1, Zhanghua Chen4, Fan Bai4, Jun Cui5, Andrew M Lew6,
Jincun Zhao1, Yan Zhang1*, Hai-Bin Luo7*, and Yuxia Zhang1,8*

1

Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State

Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou, 510623,
China
2

Department of Pediatric Surgery , Guangzhou women and Children's Medical Center ,

Guangzhou Medical University, Guangzhou, 510623, China
3

Department of Neonatology, Guangzhou Women and Children's Medical Centre, Guangzhou

Medical University, Guangzhou, 510623, China
4

Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University,

Beijing, 100871, China
5

School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, 510006, China

6

Walter and Eliza Hall Institute of Medical Research and Departments of Medical Biology and

Microbiology & Immunology, University of Melbourne, Parkville, Melbourne, Victoria 3052,
Australia.
7

School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou, Guangdong, 510006,

China
8

The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

#

These authors contributed equally.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

*Correspondence to:
yannizy@gmail.com
luohb77@mail.sysu.edu.cn
yuxia.zhang@gwcmc.org

ABSTRACT
Respiratory disease caused by the 2019 novel coronavirus (2019-nCoV) pneumonia first
emerged in Wuhan, Hubei Province, China, in December 2019 and spread rapidly to other
provinces and other countries. Angiotensin-converting enzyme 2 (ACE2) is the receptor for
SARS-CoV and has been suggested to be also the receptor for 2019-nCoV. Paradoxically, ACE2
expression in the lung protects mice from SARS-CoV spike protein induced lung injury by
attenuating the renin-angiotensin system. In the intestine, ACE2 also suppresses intestinal
inflammation by maintaining amino acid homeostasis, antimicrobial peptide expression and
ecology of the gut microbiome. Upon analysis of single cell-RNA sequencing data from control
subjects and those with colitis or inflammatory bowel disease (IBD), we found that ACE2
expression in the colonocytes was positively associated with genes regulating viral infection,
innate and cellular immunity, but was negatively associated with viral transcription, protein
translation, humoral immunity, phagocytosis and complement activation. In summary, we
suggest that ACE2 may play dual roles in mediating the susceptibility and immunity of 2019nCoV infection.

Patients infected by 2019-nCoV can develop acute respiratory distress syndrome (ARDS) and
sepsis. However, there is mounting evidences that the gastrointestinal tract may be an alternative

2

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

route for 2019-nCoV infection. One (3%) of the first 41 reported cases had diarrhea [1]. In
another report describing a familial cluster, 2 of the 6 family members (33%) developed
diarrhea[2]. Furthermore, positive 2019-nCoV was detected from the stools of a patient with
loose of bowel movement in the United States [3].

There have been many studies on the proteins associated with host entry by the SARS-CoV.
Cleavage of Spike protein by tissue factor Xa is required for the infectivity of SARS-CoV [4].
Rivaroxaban is an oral anticoagulant used to combat acute pulmonary embolism with or without
deep-vein thrombosis [5]. As an Xa inhibitor, it may thus offer protection for 2019-nCoV
pneumonia. Angiotensin I converting enzyme 2 (ACE2) is the SARS-CoV receptor [6]. It also
has been linked to 2019-nCoV infection; ACE2 interacts with the Spike protein and mediates
2019-nCoV infection of the type II alveolar cells of the lung [7].

Paradoxically, although ACE2 mediates viral entry to the host, its deficiency worsens lung injury
by activating the renin-angiotensin system (RAS) in experimental models [6]. The circulating
RAS regulates blood pressure and fluid homeostasis. Local tissue-based RAS exacerbates
pulmonary hypertension, acute lung injury and experimental lung fibrosis [8]. Thus, blocking of
the Angiotensin II receptor type I (AT1R) was associated with reduced SARS-CoV spike protein
mediated lung injury [6] and reduced pulmonary hypertension in experimental models [9]. The
AT1R blocker valsartan has recently been reported to improve clinical outcomes for patients
with chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension
(DOI:10.1183/13993003.congress-2019.PA2469). In the PARADIGM-HF trial, valsartan and the

3

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

neprilysin inhibitor prodrug sacubitril (Valsartan/sacubitril, branded Entresto by Novartis) also
significantly reduced mortality and hospitalization for patients with heart failure [10].

Apart from the lung, ACE2 is also associated with gut function. ACE2 expression in the gut
epithelial cells is required for maintaining amino acid homeostasis, antimicrobial peptide
expression and the ecology of gut microbiome in the intestine [11, 12]. We had previously
generated a single-cell RNA sequencing dataset from control subjects and those with colitis or
IBD [13]. Using this dataset, we examined ACE2 expression and found that it was specifically
and highly expressed by the colonocytes (Figure 1 A-B). Compared with other epithelial
subtypes, colonocytes overexpressed genes regulating viral entry, budding and releasing from the
host cells (VAPA, CHMP4C, CHMP1A, CHMP2B, CHMP4B, CHMP1B, VPS37B, PDCD6IP,
VPS4B, CHMP3, VPS28, CHMP2A, PVRL2, CDH1, and MVB12A). Genes involved in nucleic
acid sensing and type I, type III interferon signaling (R2RX4, DDX58, NLRC5, IFNAR2, IFNGR1
and IFNGR2), pro-inflammatory cytokine and chemokine (IL18, IL32, CXCL16, CXCL3, CXCL2,
CXCL1, CCL28, CCL20) production, antigen presentation via MHC class I molecules (HLA-A,
HLA-B, HLA-C, and HLA-E) and cytokine receptors (IL2G, IL10RB, and IL6R) were also
enriched in colonocytes (Figure 1C).

Given that ACE2 plays dual roles in mediating viral entry and preventing tissue injury [6, 11, 12,
14], we analyzed genes that are co-expressed with ACE2 in the colonic epithelial cells. In total,
3420 and 2136 genes were positively and negatively correlated with ACE2 expression,
respectively (Supplementary table 1 and Figure 2A). In Gene Ontology (GO) analysis, genes
positively correlated with ACE2 expression were enriched in viral infection and egress (viral

4

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

budding via host ESCRT complex, positive regulation of viral release from host cells, viral entry
into host cells), innate immune responses (type I interferon signaling pathway and toll-like
receptor signaling pathway), NK and T cell cytotoxicity (interferon-gamma-mediated signaling
pathway, regulation of natural killer cell mediated immunity, positive regulation of T cell
mediated cytotoxicity), energy metabolism (triglyceride biosynthetic process, pyruvate metabolic
process, NADH metabolic process, mitochondrial electron transport), inflammation and
apoptosis (positive regulation of I-kappaB kinase/NF-kappaB signaling and positive regulation
of apoptotic signaling pathway). In contrast, genes negatively correlated with ACE2 were
enriched for humoral immunity (positive regulation of B cell activation, antibacterial humoral
response, mature B cell differentiation, B cell receptor signaling pathway, immunoglobulin
production), protein translation (ribosomal big and small subunit assembly and translational
initiation), phagocytosis (Fc-epsilon receptor signaling pathway, Fc-gamma receptor signaling
pathway involved in phagocytosis, phagocytosis recognition) and classical pathway of
complement activation (Figure 2B).

Discussion
Here we report the expression pattern of ACE2 in the human intestine at single-cell resolution.
Our data suggest that ACE2 is specifically expressed by colonocytes and positively associated
with viral entry and egress, consistent with observations that the gastrointestinal tract is a
potential route for 2019-nCoV infection. In supportive of the view that ACE2 expression
prevents intestinal inflammation [11, 12], bioinformatic analysis suggested that genes regulating
type I and type III innate immunity, NK and T cell mediated cytotoxicity and energy metabolism
are positively associated with ACE2 expression. By contrast, humoral immunity, phagocytosis

5

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

and complement activation are negatively associated with ACE2 expression. These findings may
facilitate concurrent and future investigations of the nature and function of the immune system at
systemic and local levels in patients with 2019-nCoV pneumonia.

Notably, SARS-CoV spike protein engagement downregulates ACE2 expression and activates
the RAS [6]. Given that hypertension is common in severe 2019-nCoV pneumonia [1], it is
highly likely that the RAS is activated in the lungs of patients with severe pneumonia. The Xa
inhibitor Rivaroxaban [5] and the AT1R blocker valsartan (DOI:10.1183/13993003.congress2019.PA2469) are effective in relieving pulmonary injury and embolism in experimental models
and clinical trials, their efficacy in treating 2019-nCoV may worth consideration. Dipyridamole
is another anti-coagulation drug. In a pilot trial, dipyridamole administration promoted mucosal
healing and improved clinical symptoms in patients with colitis or IBD [13]. More importantly,
published clinical studies [15-20], including those conducted in China (DOI:
CNKI:SUN:XIYI.0.2010-12-026;[21]; CNKI:SUN:YXLT.0.2014-32-031), have demonstrated
that dipyridamole has broad spectrum antiviral activity against virus infections. It may also be
worth investigating the therapeutic effects of dipyridamole in patients infected by 2019-nCoV.

Methods
Ethical statement
The study procedures (ID: 2017021504) were approved by the Medical Ethics Committee of
Guangzhou Women and Children's Medical Center. The implementations were in concordance
with the International Ethical Guidelines for Research Involving Human Subjects stated in the

6

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Helsinki Declaration. Informed written consents from the legal guardians of all participants were
obtained before conducting these procedures.

Single cell RNA sequencing data analysis
Colonic biopsies from 17 children (6 control, 6 colitis, 2 ulcerative colitis, 3 Crohn's disease)
were subjected to single-cell suspension preparation, 5 ' gene expression libraries construction,
and 10x Genomics single-cell RNA sequencing [13]. Cellranger v2.1 pipeline (10x genomics)
was utilized to demultiplex the cellular barcodes and align reads to the human transcriptome
(build GRCh38). The unique molecular identifier (UMI) count matrix was converted to Seurat
object using the R package Seurat v2.3.4 [22]. After quality control and data normalization,
dimension reduction and cell clustering were performed [13]. Different cell types were identified
by mapping canonical marker genes in the two-dimensional t-Distributed Stochastic Neighbor
embedding (tSNE) map [13].

Co-expression analysis
Normalized single-cell RNA expression data was used for co-expression analysis. Pearson's
correlation analysis was performed between each gene in the single-cell transcriptome and ACE2.
Significantly correlated genes were chosen (p-value<0.05) for downstream GO enrichment
analysis via GENEONTOLOGY at http://geneontology.org/. GO terms with False Detection
Rate (FDR) <0.05 were selected.

Acknowledgments

7

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

National Natural Sc The ience Foundation of China (91742109, 31770978, 31722003, 31770925,
31370847, 81770552), National Key Research and Development Program (2016YFC0900102),
National Science and Technology Major Project (2018ZX10302205), Guangdong Provincial Key
Laboratory of Research in Structural Birth Defect Disease (2019B030301004), Guangzhou
Women and Childrenâ€™s Medical Center Fund (5001-3001032) and National Health and Medical
Research Council of Australia (1037321, 1105209, 1143976, and 1080321 to A.L.) funded this
study.

Author Contributions
Yuxia.Z., H-B.L., and Yan.Z. conceived of and supervised the project. J.W. performed the
bioinformatic analysis. S.Z., M.L., Z. Z., Yiping.X, P.W, M. L., Yanhui.X., B.H., Xiaoyu.Z. and
Z.C. reviewed and discussed the manuscript. Yuxia.Z. and J.W. wrote the manuscript with
significant input from A.M.L., J.C., F.B. and All authors discussed and approved the manuscript.

Figures and legends

8

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 1. ACE2 was highly and specifically expressed by colonocytes. A. Left panel: twodimensional tSNE plot displaying major cell clusters; right panel: heatmap displaying ACE2
expression across major cell clusters. B. Left panel: distribution of 10 epithelial sub-clusters on
the tSNE plot; right panel: heatmap showing ACE2 expression across epithelial clusters. C.
Heatmap plot showing expression of selected genes across 10 epithelial clusters.

9

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 2. Genes correlated with ACE2 expression in colonocytes. A. Valcano plot displaying
genes co-expressed with ACE2. B. Bar plot presenting significantly enriched GO terms obtained
from GO enrichment analysis performed with aforementioned ACE2 co-expressed genes.

Supplementary Table 1 Genes correlated with ACE2 expression.

References
1.

Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet, 2020.

2.

Jasper Fuk-Woo Chan, S.Y., Kin-Hang Kok, Kelvin Kai-Wang To, Hin Chu, Jin Yang,
Fanfan Xing, Jieling Liu, Cyril Chik-Yan Yip, Rosana Wing-Shan Poon, Hoi-Wah Tsoi,
Simon Kam-Fai Lo, Kwok-Hung Chan, Vincent Kwok-Man Poon, Wan-Mui Chan,
Jonathan Daniel Ip, and V.C.-C.C. Jian-Piao Cai, Honglin Chen, Christopher Kim-Ming

10

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Hui, Kwok-Yung Yuen, A familial cluster of pneumonia associated with the 2019 novel
coronavirus indicating person-to-person transmission:a study of a family cluster. Lancet,
2020.
3.

Holshue, M.L., et al., First Case of 2019 Novel Coronavirus in the United States. N Engl
J Med, 2020.

4.

Du, L., et al., Cleavage of spike protein of SARS coronavirus by protease factor Xa is
associated with viral infectivity. Biochemical and biophysical research communications,
2007. 359(1): p. 174-179.

5.

Investigators, E.-P., et al., Oral rivaroxaban for the treatment of symptomatic pulmonary
embolism. N Engl J Med, 2012. 366(14): p. 1287-97.

6.

Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
coronavirus-induced lung injury. Nat Med, 2005. 11(8): p. 875-9.

7.

Chan, J.F., et al., Genomic characterization of the 2019 novel human-pathogenic
coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg
Microbes Infect, 2020. 9(1): p. 221-236.

8.

Marshall, R.P., The pulmonary renin-angiotensin system. Curr Pharm Des, 2003. 9(9): p.
715-22.

9.

Clements, R.T., et al., Treatment of Pulmonary Hypertension With Angiotensin II
Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan. Circ Heart Fail, 2019.
12(11): p. e005819.

10.

Hubers, S.A. and N.J. Brown, Combined Angiotensin Receptor Antagonism and
Neprilysin Inhibition. Circulation, 2016. 133(11): p. 1115-24.

11

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

11.

Hashimoto, T., et al., ACE2 links amino acid malnutrition to microbial ecology and
intestinal inflammation. Nature, 2012. 487(7408): p. 477-81.

12.

Vuille-dit-Bille, R.N., et al., Human intestine luminal ACE2 and amino acid transporter
expression increased by ACE-inhibitors. Amino Acids, 2015. 47(4): p. 693-705.

13.

Huang, B., et al., Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common
Pathogenics and Therapeutic Pathways. Cell, 2019. 179(5): p. 1160-1176 e24.

14.

Ye, R. and Z. Liu, ACE2 exhibits protective effects against LPS-induced acute lung
injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol, 2019. 113: p.
104350.

15.

Tonew, E., M.K. Indulen, and D.R. Dzeguze, Antiviral action of dipyridamole and its
derivatives against influenza virus A. Acta Virol, 1982. 26(3): p. 125-9.

16.

Fata-Hartley, C.L. and A.C. Palmenberg, Dipyridamole reversibly inhibits mengovirus
RNA replication. J Virol, 2005. 79(17): p. 11062-70.

17.

Tenser, R.B., A. Gaydos, and K.A. Hay, Inhibition of herpes simplex virus reactivation
by dipyridamole. Antimicrob Agents Chemother, 2001. 45(12): p. 3657-9.

18.

Szebeni, J., et al., Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine
and other dideoxynucleosides of human immunodeficiency virus replication in monocytemacrophages. Proc Natl Acad Sci U S A, 1989. 86(10): p. 3842-6.

19.

Kozhukharova, M.S., et al., [Evaluation of dipyridamole efficacy as an agent for
preventing acute respiratory viral diseases]. Vopr Virusol, 1987. 32(3): p. 294-7.

20.

Kuzmov, K., et al., [Epidemiological trial of the prophylactic effectiveness of the
interferon inducer dipyridamole with respect to influenza and acute respiratory diseases].
Zh Mikrobiol Epidemiol Immunobiol, 1985(6): p. 26-30.

12

medRxiv preprint doi: https://doi.org/10.1101/2020.02.05.20020545; this version posted February 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

21.

Hu, X.Q. and X.L. wANG, Treatment of viral upper respiratory tract infection in
children with dipyridamole. Chinese Journal of Hospital Pharmacy, 1995(9).

22.

Butler, A., et al., Integrating single-cell transcriptomic data across different conditions,
technologies, and species. Nat Biotechnol, 2018. 36(5): p. 411-420.

13

